# Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer

Source: https://onco.cc/trials/nct00833248/  
OnCo record `nct00833248` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Degarelix, Goserelin / leuprolide and Bicalutamide in Prostate cancer, run by Ferring Pharmaceuticals, completed.

## Summary

Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer is a phase 3 interventional study registered as NCT00833248 by Ferring Pharmaceuticals, with 246 participants recorded, started 2009-04 and reaching its primary completion in 2011-09. Interventions recorded: Degarelix, Goserelin, Bicalutamide. Conditions recorded: Prostate Cancer.

Linked to the drug Degarelix because the registry names it among its interventions and Prostate cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT00833248
- Phase: 3
- Setting: A Randomised, Parallel Arm, Open-label Trial Comparing Degarelix With Goserelin Plus Anti-androgen Flare Protection (Bicalutamide), in Terms of Prostate Size Reduction in Prostate Cancer Patients of Intermediate-to-high Risk, Who Require Neoadjuvant Hormone Therapy Prior to Radiotherapy (Curative Intent)
- Sponsor: Ferring Pharmaceuticals
- Enrolled: 246

## Sources

- ClinicalTrials.gov NCT00833248: https://clinicaltrials.gov/study/NCT00833248

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- drugs: [Bicalutamide](https://onco.cc/drugs/bicalutamide/), [Degarelix](https://onco.cc/drugs/degarelix/), [Goserelin / leuprolide (ovarian function suppression)](https://onco.cc/drugs/goserelin/)
- companies: [Ferring Pharmaceuticals](https://onco.cc/companies/ferring/)

---
JSON: https://onco.cc/api/v1/entities/nct00833248.json